Serum fibroblast growth factor-23 levels and progression of aortic arch calcification in non-diabetic patients on chronic hemodialysis

Journal of Atherosclerosis and Thrombosis

Volumn 18, Issue 3, 2011, Pages 217-223

  Tamei, Noriko ^a,b   Ogawa, Tetsuya ^a   Ishida, Hideki ^b   Ando, Yoshitaka ^b   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Hidaka Hospital   (Japan)

Author keywords

Aortic arch calcification; Cardiovascular disease; Chest radiography; Fibroblast growth factor 23; Hemodialysis

Indexed keywords

FIBROBLAST GROWTH FACTOR 23;

ADULT; AGED; ARTERY CALCIFICATION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; THORAX RADIOGRAPHY; TREATMENT DURATION;

EID: 79953312305     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.5595     Document Type: Article

References (33)

1. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998- 1999. J Am Soc Nephrol, 2005; 16: 489-495
2. Tsushima M, Terayama Y, Momose A, Funyu T, Ohyama C: Progression of atherosclerosis in hemodialysis patients: Effect of adiponectin on carotid intima media thickness. J Atheroscler Thromb, 2008; 15: 213-218
3. Takenaka T, Hoshi H, Kato N, Kobayashi K, Takanne H, Shoda J, Suzuki H: Cardio-ankle vascular index to screen cardiovasculatr diseases in patients with end-stage renal diseases. J Atheroscler Thromb, 2008; 15: 339-344
4. Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B: (2006) Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol, 2006; 17(12 Suppl 3): S267-S273
5. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol, 2002; 39: 695-701
6. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulations of vascular smooth muscle cell calcification. Circ Res, 2000; 87: E10-E17
7. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H: Vascular calcification and inorganic phosphate. Am J Kidney Dis, 2001; 38 [4 Suppl 1]: S34-S37
8. Son BK, Akishita M, Iijima K, Eto M, Ouchi Y: Mechanism of Pi-induced vascular calcification. J Atheroscler Thromb, 2008; 15: 63-68
9. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcification in end-stage renal disease. Nephrol Dial Transplant, 2000; 15: 1014-1021
10. Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM: Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol, 1998; 18: 535-541
11. Pan N-H, Yang H-Y, Hsieh M-H, Chen Y-J: Coronary calcium score from multislice computed tomography correlates with QT dispersion and left ventricular wall thickness. Heart Vessels, 2008; 23: 155-160
12. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y: FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int, 2004; 65: 1943-1946
13. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M: Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int, 2005; 67:1171-1178
14. Ibrahim S, Rashed L: Serum fibroblast growth factor-23 levels in chronic haemodialysis patients. Int Urol Nephrol, 2009; 41: 163-169
15. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M: Fibroblast growth factor-23 and left ventricular hypertrophy in chronic kidney disease. Circulation, 2009; 119: 2545-2552
16. Kojima F, Uchida K, Ogawa T, Tanaka Y, Nitta K: Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis. Int Urol Nephrol, 2008; 40: 1067-1074
17. Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J Am Soc Nephrol, 1993; 4: 1205-1213
18. Ogawa T, Ishida H, Matsuda N, Fujiu A, Matsuda A, Ito K, Ando Y, Nitta K: Simple evaluation of aortic arch calcification by chest radiography in hemodialysis patients. Hemodial Int, 2009; 13: 301-306
19. Hashimoto H, Iijima K, Hashimoto M, Son BK, Ota H, Ogawa S, Eto Masato, Akishita M, Ouchi Y: Validity and usefulness of aortic arch calcification in chest X-ray. J Atheroscler Thromb, 2008; 16: 256-264
20. Iribarren C, Sidney S, Sternfeld B, Browner WS: Calcification of the aortic arch: risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA, 2000; 283: 2810-2815
21. Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, Ketteler M, Levin A, Massy Z, McCarron DA, Raggi P, Shanahan CM, Yorioka N; Vascular Calcification Work Group: Vascular calcification in chronic kidney disease. Am J Kidney Dis, 2004; 43: 572-579
22. Witteman JC, Kannel WB, Wolf PA, Grobbee DE, Hofman A, D'Agostino RB, Cobb JC: Aortic calcified plaques and cardiovascular disease (the Framingham Study). Am J Cardiol, 1990; 66: 1060-1064
23. Witteman JC, Kok FJ, van Saase JL, Valkenburg HA: Aortic calcification as a predictor of cardiovascular mortality. Lancet, 1986; 2: 1120-1122
24. Li J, Galvin HK, Johnson SC, Langston CS, Sclamberg J, Preston CA: Aortic calcification on plain chest radiography increases risk for coronary artery disease. Chest, 2002; 121: 1468-1471
25. Salgueira M, del Toro N, Moreno-Alba: Vascular calcification in the uremic patient: a cardiovascular risk? Kidney Int, 2003; 63 (Suppl 85): S119-S121
26. Fujiu A, Ogawa T, Matsuda N, Ando Y, Nitta K: Aortic arch calcification and arterial stiffness are independent factors for diastolic left ventricular dysfunction in chronic hemodialysis patients. Circ J, 2008; 72: 1768-1772
27. National Kidney Foundation: KDOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis, 2003; 42 (Suppl 3): 1-201
28. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B: An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet, 2005; 14: 385-390
29. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest, 2004; 113: 561-568
30. Razzaque MS, St-Arnaud R, Taguchi T, Lanske B: FGF-23, vitamin D and calcification: the unholy triad. Nephrol Dial Transplant, 2005; 20: 2032-2035
31. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA: Fibroblast growth factor- 23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant, 2010; 25: 2679-2685
32. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadnari R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int, 2007; 72: 1004-1013
33. Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, Nii-Kono T, Fukagawa M, Shigematsu T; ROD21 Clinical Research Group: Sevelamer hydrochloride and calcium bicarbonate reduce fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial, 2005; 9: 336-339